Medication info
Olmesartan Medoxomil/Amlodipine Besylate/Hydrochlorothiazide Tablet 5/40/12.5 mg

Olmesartan Medoxomil/Amlodipine Besylate/Hydrochlorothiazide Tablet 5/40/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
JW Pharmaceutical Co., Ltd.
Appearance
Light yellow round film-coated tablet
Packaging
28 tablets (14 tablets/PTP X 2)/carton
Approval status
Active

MFDS item code 201805228 · Approved 2018.12.21 · Insurance code 644914600

Summary

Main use
Treatment of essential hypertension not controlled with concomitant amlodipine and olmesartan
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended to adjust the dose using the individual components (olmesartan medoxomil and amlodipine, as monotherapy or combination therapy). However, if blood pressure is not controlled with the combination of amlodipine and olmesartan medoxomil as described below, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. As the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The amounts of the individual components are listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg □ Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). □ Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild or moderate hepatic impairment. The maximum dose for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. □ Older adults (65 years or older) Treatment is generally initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into account. Blood pressure should be monitored closely and more frequently in older adults. As experience with this medicine in older adults, particularly those aged 75 years or older, is very limited, patients should be monitored very carefully when receiving this medicine.
Child dose
Pediatric patients under 18 years of age: Safety and efficacy have not been established; use of this medicine is not recommended.

Ingredients

Manufacturer
JW Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with concomitant amlodipine and olmesartan

  • Essential hypertension
View approved original text

In cases where blood pressure is not adequately controlled due to essential hypertension, the combination therapy of Amlodipine and Olmesartan Medoxomil can effectively lower and control blood pressure. These two drugs help expand blood vessels and suppress blood pressure rises, thereby reducing the burden on the cardiovascular system. Regular use of this medication can help decrease the risk of complications due to hypertension. Therefore, this drug is used to treat essential hypertension.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended to adjust the dose using the individual components (olmesartan medoxomil and amlodipine, as monotherapy or combination therapy). However, if blood pressure is not controlled with the combination of amlodipine and olmesartan medoxomil as described below, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. As the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The amounts of the individual components are listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg □ Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). □ Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild or moderate hepatic impairment. The maximum dose for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. □ Older adults (65 years or older) Treatment is generally initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into account. Blood pressure should be monitored closely and more frequently in older adults. As experience with this medicine in older adults, particularly those aged 75 years or older, is very limited, patients should be monitored very carefully when receiving this medicine.

Child dose

Pediatric patients under 18 years of age: Safety and efficacy have not been established; use of this medicine is not recommended.

Precautions

This medication should not be used during the second and third trimesters of pregnancy. Taking it during pregnancy may cause serious harm to the fetus or newborn, so usage must be stopped immediately upon confirmation of pregnancy. Patients with a history of allergy or hypersensitivity to any components of this medication or similar drugs, pregnant or nursing women, patients with severe hypotension or heart valve diseases, and those with unstable heart failure following acute myocardial infarction should not be administered this drug. Patients with severely impaired kidney or liver function, hyponatremia, hypokalemia, hypercalcemia, gout, and certain other conditions should use this medication carefully and frequently monitor blood pressure, kidney function, and electrolyte levels before and during treatment. Since this drug has a blood pressure-lowering effect, it may cause low blood pressure leading to dizziness or orthostatic hypotension. If these symptoms occur, notify healthcare professionals immediately, and be cautious when driving or operating hazardous machinery. This drug can interact with other antihypertensive medications, diuretics, lithium, non-steroidal anti-inflammatory drugs (NSAIDs), so inform healthcare professionals of any other medications being taken. During treatment, regular blood tests to monitor kidney function, electrolytes, blood glucose, and cholesterol levels are necessary, and consult a doctor if any unusual symptoms occur. This medication is not recommended for nursing women, and if necessary, breastfeeding should be discontinued or alternative treatment options considered. In cases of overdose, severe hypotension, palpitations, bradycardia, and electrolyte imbalances may occur, requiring immediate medical attention at a hospital. This medication should be stored in a tightly sealed container, away from direct sunlight and moisture, out of reach of children, and should not be transferred to different containers.

Side effects

Peripheral edema, headache, dizziness, upper respiratory tract infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, anorexia, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, irritability, anxiety, mood changes, sleep disturbances, orthostatic dizziness, syncope, taste disturbances, hypertonicity, sensory impairment, dysesthesia, peripheral neuropathy, drowsiness, syncope, seizures, loss of appetite, tremor, visual disturbances, decreased tears, worsening myopia, jaundice, dizziness, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, acute respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, change in bowel habits, bloating, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, skin lupus erythematosus-like reaction, exanthematous pustulosis, exfoliative dermatitis, sweating, photosensitivity reaction, pruritus, purpura, Quincke's edema, rash, recurrence of skin lupus erythematosus, toxic dermal necrosis, skin discoloration, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, polyuria, acute renal failure, hematuria, urination disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, malaise, fatigue, chest pain, fever, influenza-like symptoms, lethargy, fatigue, edema, pain, facial edema, elevated blood creatinine, elevated blood urea, elevated blood uric acid, decreased blood potassium, increased gamma-glutamyl transferase, increased alanine aminotransferase, increased aspartate aminotransferase, elevated liver enzymes, elevated blood creatinine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, intestinal vascular edema, altered consciousness, drug hypersensitivity, epigastric pain, decreased libido, scrotal edema, malaise, loss of consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distension, facial flushing, nosebleed, benign prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute hearing loss, lymphadenitis, acute respiratory distress syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent air or moisture ingress, at a temperature between 1 to 30 degrees Celsius room temperature. This storage method will help maintain the drug's efficacy for a longer period.

Appearance and packaging

Appearance

Light yellow round film-coated tablet

Package unit

28 tablets (14 tablets/PTP X 2)/carton

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.